This CME activity is jointly sponsored by The Angiogenesis Foundation and The Institute for Medical Studies.

This activity is supported by an educational grant from Astra Zeneca; Bristol-Myers Squibb; Merck and Co., Inc.; Pfizer, Inc.; Sanofi-Aventis.

---

ACCREDITATION STATEMENT

This CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) thru the Joint Sponsorship of the Institute for Medical Studies (IMS) and the Angiogenesis Foundation. IMS is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION

IMS designates this educational activity for a maximum of two (2) AMA PRA Category 1 Credits. Physicians should claim only those hours of credit that he/she spent in the educational activity.

Nurses may claim credit for activities approved for AMA PRA Category 1 Credits in most states, for up to 50% of the nursing requirement for recertification. This activity is designated for up to 2 hours of AMA PRA Category 1 Credits.

Release and Experation Dates

The release date of this activity is August, 2007.
Credit is valid thru July, 2008.

INTENDED AUDIENCE

Practicing oncologists and oncology nurses in the US.

EDUCATIONAL OBJECTIVES

• Describe angiogenesis targets and pathways in cancer
• Describe the paradigm shifts in cancer management accompanying antiangiogenic therapy
• Review clinical data regarding the use of antiangiogenic agents in treating metastatic colorectal cancer

METHOD OF PARTICIPATION

Review the illustrations on the corresponding wall chart, and then visit the website for additional content, CME registration and evaluation.

---

Faculty Disclosure

Axel Grothey, M.D., has a financial interest/relationship or affiliation in the form of:

• Honoraria from Genentech, Amgen, Bristol-Myers Squibb, Roche, Sanofi-Aventis
• Consultant to Genentech, Amgen, Bristol-Myers Squibb, Roche, Sanofi-Aventis
• Research support from Sanofi-Aventis

Mark Kozloff, M.D., has a financial interest/relationship or affiliation in the form of:

• Consultant to Genentech

William Li, M.D.

• Has no relationships to disclose that are germane to this CME activity

Lee Rosen, M.D.

• Has no relationships to disclose that are germane to this CME activity

Written by Rod Smith, Medical Writer and Editor, The Angiogenesis Foundation.

• Has no relationships to disclose that are germane to this CME activity

Stanley Golanty, MD, CME Advisor. Dr. Golanty has no relationships to disclose that are germane to this CME activity.

---

DISCUSSION OF UNLABELED USE

This CME activity contains discussion of published and/or investigational use of bevacizumab (approved for metastatic colorectal cancer in combination with 5-FU and advanced non-small cell lung cancer in combination with carboplatin and paclitaxel), cetuximab (approved as therapy for refractory metastatic colorectal cancer), vatalanib (PTK787/ZK), and sunitinib (approved as therapy for advanced renal cell carcinoma and gastrointestinal stromal tumors).

The information presented in this CME activity is for educational purposes only and is not intended to serve as a guideline for patient management. The opinions expressed are those of the faculty and authors, and not necessarily that of IMS, The Angiogenisis Foundation or the commercial supporters of this CME activity.